Clinical development of RNA-based medicines has expanded beyond infectious diseases into rare genetic metabolic conditions, with several candidates advancing into pivotal Phase III trials. The shift follows key breakthroughs in targeted delivery vehicles that bypass systemic clearing mechanisms.
Delivery System Optimization
Engineered lipid nanoparticles (LNPs) modified with tissue-specific targeting ligands have demonstrated reduced off-target liver accumulation in early clinical cohorts. This optimization allows lower dosing regimens, significantly improving long-term therapeutic safety profiles.